<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34775963</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>14</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Neutralization of interleukin-38 exacerbates coxsackievirus B3-induced acute myocarditis in mice.</ArticleTitle><Pagination><StartPage>220</StartPage><MedlinePgn>220</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">220</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-021-01687-w</ELocationID><Abstract><AbstractText Label="BACKGROUND">Interleukin (IL)-38, a novel member of the IL-1 family, has been reported to be involved in several diseases associated with viral infection. However, the expression and functional role of IL-38 in acute viral myocarditis (AVMC) have not been investigated.</AbstractText><AbstractText Label="METHODS">Male BALB/c mice were treated with intraperitoneal (i.p.) injection of coxsackievirus B3 (CVB3) for establishing AVMC models. On day 7 post-injection, the expression of IL-38 and IL-36R (IL-36 receptor) were measured. Mice were then treated with i.p. injection of mouse Anti-IL-38 Antibodies (Abs) for neutralization of IL-38. The survival, bodyweight loss, cardiac function, and myocarditis severity of mice were recorded. The percentages of splenic Th1 and Th17 cells, the expression levels of Th1/Th17-related master transcription factors (T-bet and ROR&#x3b3;t) and cytokines were determined by flow cytometry, RT-qPCR, and ELISA, respectively. Cardiac viral replication was further detected.</AbstractText><AbstractText Label="RESULTS">The mRNA and protein expression levels of IL-38 in myocardium and serum, as well as cardiac IL-36R mRNA levels were significantly elevated in mice with AVMC. Increased IL-38 levels were negatively correlated with the severity of AVMC. Neutralization of IL-38 exacerbated CVB3-induced AVMC, as verified by the lower survival rate, impaired cardiac function, continuous bodyweight loss, and higher values of HW/BW and cardiac pathological scores. In addition, neutralization of IL-38 suppressed Th1 cells differentiation while promoted Th17 cells differentiation, accompanied by decreased T-bet mRNA expression and increased ROR&#x3b3;t expression. Down-regulation of IFN-&#x3b3; and up-regulation of IL-17, TNF-&#x3b1;, and IL-6 mRNA and protein expression levels in myocardium and serum were also observed in the IL-38 neutralization group. Furthermore, neutralization of IL-38 markedly promoted cardiac viral replication.</AbstractText><AbstractText Label="CONCLUSIONS">Neutralization of IL-38 exacerbates CVB3-induced AVMC in mice, which may be attributable to the imbalance of Th1/Th17 cells and increased CVB3 replication. Thus, IL-38 can be considered as a potential therapeutic target for AVMC.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Yimin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, Fujian, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Fourth Department of Intensive Care Unit, Fujian Provincial Hospital, Fuzhou, 350001, Fujian, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Emergency Medicine, Fuzhou, 350001, Fujian, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Mingguang</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, Fujian, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Fourth Department of Intensive Care Unit, Fujian Provincial Hospital, Fuzhou, 350001, Fujian, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, Fujian, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Fourth Department of Intensive Care Unit, Fujian Provincial Hospital, Fuzhou, 350001, Fujian, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Tingfeng</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, Fujian, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Fourth Department of Intensive Care Unit, Fujian Provincial Hospital, Fuzhou, 350001, Fujian, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Qiaolian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, Fujian, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Fourth Department of Intensive Care Unit, Fujian Provincial Hospital, Fuzhou, 350001, Fujian, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Fenghui</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, Fujian, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Fourth Department of Intensive Care Unit, Fujian Provincial Hospital, Fuzhou, 350001, Fujian, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ke</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, Fujian, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency, Fujian Provincial Hospital, Fuzhou, 350001, Fujian, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Emergency Medicine, Fuzhou, 350001, Fujian, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Feng</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-4419-9707</Identifier><AffiliationInfo><Affiliation>Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, Fujian, People's Republic of China. fjslchenfeng@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency, Fujian Provincial Hospital, Fuzhou, 350001, Fujian, People's Republic of China. fjslchenfeng@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Emergency Medicine, Fuzhou, 350001, Fujian, People's Republic of China. fjslchenfeng@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000627769">Il1f10 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="Y">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007375" MajorTopicYN="Y">Interleukin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058504" MajorTopicYN="N">Th17 Cells</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute viral myocarditis</Keyword><Keyword MajorTopicYN="N">Coxsackievirus B3</Keyword><Keyword MajorTopicYN="N">IL-38</Keyword><Keyword MajorTopicYN="N">Th1 cells</Keyword><Keyword MajorTopicYN="N">Th17 cells</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>15</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34775963</ArticleId><ArticleId IdType="pmc">PMC8590870</ArticleId><ArticleId IdType="doi">10.1186/s12985-021-01687-w</ArticleId><ArticleId IdType="pii">10.1186/s12985-021-01687-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>K&#xfc;hl U, Schultheiss HP. Viral myocarditis: diagnosis, aetiology and management. Drugs. 2009;69(10):1287&#x2013;1302. doi: 10.2165/00003495-200969100-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-200969100-00001</ArticleId><ArticleId IdType="pubmed">19583449</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng C, Wu SM, Lian H, Lin YZ, Zhuang R, Thapa S, Chen QZ, Chen YF, Lin JF. Low-intensity pulsed ultrasound attenuates cardiac inflammation of CVB3-induced viral myocarditis via regulation of caveolin-1 and MAPK pathways. J Cell Mol Med. 2019;23(3):1963&#x2013;1975. doi: 10.1111/jcmm.14098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.14098</ArticleId><ArticleId IdType="pmc">PMC6378187</ArticleId><ArticleId IdType="pubmed">30592150</ArticleId></ArticleIdList></Reference><Reference><Citation>Poller W, Schultheiss HP, K&#xfc;hl U. Viruses and other environmental factors as possible sources of phenotypic heterogeneity in familial dilated cardiomyopathy. J Am Coll Cardiol. 2006;47(3):689&#x2013;690. doi: 10.1016/j.jacc.2005.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2005.11.004</ArticleId><ArticleId IdType="pubmed">16458162</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;oletti L, L&#xe9;v&#xea;que N, Boulagnon C, Brasselet C, Fornes P. Viral causes of human myocarditis. Arch Cardiovasc Dis. 2009;102(6&#x2013;7):559&#x2013;568. doi: 10.1016/j.acvd.2009.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acvd.2009.04.010</ArticleId><ArticleId IdType="pubmed">19664576</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasrado N, Reddy J. An overview of the immune mechanisms of viral myocarditis. Rev Med Virol. 2020;30(6):1&#x2013;14. doi: 10.1002/rmv.2131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2131</ArticleId><ArticleId IdType="pubmed">32720461</ArticleId></ArticleIdList></Reference><Reference><Citation>Bracamonte-Baran W, &#x10c;ih&#xe1;kov&#xe1; D. Cardiac autoimmunity: myocarditis. Adv Exp Med Biol. 2017;1003:187&#x2013;221. doi: 10.1007/978-3-319-57613-8_10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-57613-8_10</ArticleId><ArticleId IdType="pmc">PMC5706653</ArticleId><ArticleId IdType="pubmed">28667560</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairweather D, Stafford KA, Sung YK. Update on coxsackievirus B3 myocarditis. Curr Opin Rheumatol. 2012;24(4):401&#x2013;407. doi: 10.1097/BOR.0b013e328353372d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0b013e328353372d</ArticleId><ArticleId IdType="pmc">PMC4536812</ArticleId><ArticleId IdType="pubmed">22488075</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Chen R, Zhang X, Yu Y, Yang Y, Zou Y, Ge J, Chen H, Garzino-Demo A. Blockade of interleukin-17A protects against coxsackievirus B3-induced myocarditis by increasing COX-2/PGE2 production in the heart. FEMS Immunol Med Microbiol. 2012;64(3):343&#x2013;351. doi: 10.1111/j.1574-695X.2011.00918.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-695X.2011.00918.x</ArticleId><ArticleId IdType="pubmed">22141571</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Li L, Xiao L, Shangguan J. Progranulin ameliorates coxsackievirus-B3-induced viral myocarditis by downregulating Th1 and Th17 cells. Exp Cell Res. 2018;367(2):241&#x2013;250. doi: 10.1016/j.yexcr.2018.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2018.04.001</ArticleId><ArticleId IdType="pubmed">29625085</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensen JT, Dawson PA, Mychaleckyj JC, Bowden DW. Identification of a novel human cytokine gene in the interleukin gene cluster on chromosome 2q12-14. J Interferon Cytokine Res. 2001;21(11):899&#x2013;904. doi: 10.1089/107999001753289505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/107999001753289505</ArticleId><ArticleId IdType="pubmed">11747621</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X, Peng X, Li Y, Li M. Role of IL-38 and its related cytokines in inflammation. Mediators Inflamm. 2015;2015:807976. doi: 10.1155/2015/807976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/807976</ArticleId><ArticleId IdType="pmc">PMC4383490</ArticleId><ArticleId IdType="pubmed">25873772</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Veerdonk FL, Stoeckman AK, Wu G, Boeckermann AN, Azam T, Netea MG, Joosten LA, van der Meer JW, Hao R, Kalabokis V, Dinarello CA. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci USA. 2012;109(8):3001&#x2013;3005. doi: 10.1073/pnas.1121534109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1121534109</ArticleId><ArticleId IdType="pmc">PMC3286950</ArticleId><ArticleId IdType="pubmed">22315422</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu WD, Su LC, He CS, Huang AF. Plasma interleukin-38 in patients with rheumatoid arthritis. Int Immunopharmacol. 2018;65:1&#x2013;7. doi: 10.1016/j.intimp.2018.09.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.09.028</ArticleId><ArticleId IdType="pubmed">30268016</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Hou T, Cheung E, Iu TN, Tam VW, Chu IM, Tsang MS, Chan PK, Lam CW, Wong CK. Anti-inflammatory mechanisms of the novel cytokine interleukin-38 in allergic asthma. Cell Mol Immunol. 2020;17(6):631&#x2013;646. doi: 10.1038/s41423-019-0300-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-019-0300-7</ArticleId><ArticleId IdType="pmc">PMC7264207</ArticleId><ArticleId IdType="pubmed">31645649</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu WD, Su LC, Liu XY, Wang JM, Yuan ZC, Qin Z, Zhou XP, Huang AF. IL-38: A novel cytokine in systemic lupus erythematosus pathogenesis. J Cell Mol Med. 2020;24(21):12379&#x2013;12389. doi: 10.1111/jcmm.15737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15737</ArticleId><ArticleId IdType="pmc">PMC7686966</ArticleId><ArticleId IdType="pubmed">33079487</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HJ, Jiang YF, Wang XR, Zhang ML, Gao PJ. Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B. World J Gastroenterol. 2016;22(18):4529&#x2013;4537. doi: 10.3748/wjg.v22.i18.4529.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i18.4529</ArticleId><ArticleId IdType="pmc">PMC4858634</ArticleId><ArticleId IdType="pubmed">27182162</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, Chan PKS, Lui GCY, Hui DSC, Chu IM, Sun X, Tsang MS, Chan BCL, Lam CW, Wong CK. Interleukin-38 ameliorates poly(I:C) induced lung inflammation: therapeutic implications in respiratory viral infections. Cell Death Dis. 2021;12(1):53. doi: 10.1038/s41419-020-03283-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-03283-2</ArticleId><ArticleId IdType="pmc">PMC7790341</ArticleId><ArticleId IdType="pubmed">33414457</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):327&#x2013;331. doi: 10.23812/CONTI-E.</Citation><ArticleIdList><ArticleId IdType="doi">10.23812/CONTI-E</ArticleId><ArticleId IdType="pubmed">32171193</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge Y, Huang M, Wu Y, Dong N, Yao YM. Interleukin-38 protects against sepsis by augmenting immunosuppressive activity of CD4+ CD25+ regulatory T cells. J Cell Mol Med. 2020;24(2):2027&#x2013;2039. doi: 10.1111/jcmm.14902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.14902</ArticleId><ArticleId IdType="pmc">PMC6991686</ArticleId><ArticleId IdType="pubmed">31880383</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, Lin S, Yan X, Wang C, Tu H, Yin Y, Cao J. Interleukin 38 protects against lethal sepsis. J Infect Dis. 2018;218(7):1175&#x2013;1184. doi: 10.1093/infdis/jiy289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiy289</ArticleId><ArticleId IdType="pubmed">29762676</ArticleId></ArticleIdList></Reference><Reference><Citation>Respress JL, Wehrens XH. Transthoracic echocardiography in mice. J Vis Exp. 2010;39:1738. doi: 10.3791/1738.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/1738</ArticleId><ArticleId IdType="pmc">PMC3144600</ArticleId><ArticleId IdType="pubmed">20517201</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabie N, Delfs MW, Westrich JR, Love VA, Stavrakis G, Ahmad F, Seidman CE, Seidman JG, Lichtman AH. IL-12 is required for differentiation of pathogenic CD8+ T cell effectors that cause myocarditis. J Clin Invest. 2003;111(5):671&#x2013;680. doi: 10.1172/JCI16867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI16867</ArticleId><ArticleId IdType="pmc">PMC151896</ArticleId><ArticleId IdType="pubmed">12618521</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402&#x2013;408. doi: 10.1006/meth.2001.1262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/meth.2001.1262</ArticleId><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y, Mora J, Huard A, da Silva P, Wiechmann S, Putyrski M, Schuster C, Elwakeel E, Lang G, Scholz A, Scholz T, Schmid T, de Bruin N, Billuart P, Sala C, Burkhardt H, Parnham MJ, Ernst A, Br&#xfc;ne B, Weigert A. IL-38 ameliorates skin inflammation and limits IL-17 production from &#x3b3;&#x3b4; T cells. Cell Rep. 2019;27(3):835&#x2013;46.e5. doi: 10.1016/j.celrep.2019.03.082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.03.082</ArticleId><ArticleId IdType="pubmed">30995480</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutet MA, Blanchard F, Goff Le. Response B, to: &#x201c;Does IL-38 act on macrophages and, or dendritic cells in arthritis?&#x201d; by Jiang, et al. Ann Rheum Dis. 2018;77(3): e13. 10.1136/annrheumdis-2017-211793.</Citation><ArticleIdList><ArticleId IdType="pubmed">28606971</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora J, Schlemmer A, Wittig I, Richter F, Putyrski M, Frank AC, Han Y, Jung M, Ernst A, Weigert A, Br&#xfc;ne B. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J Mol Cell Biol. 2016;8(5):426&#x2013;438. doi: 10.1093/jmcb/mjw006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmcb/mjw006</ArticleId><ArticleId IdType="pubmed">26892022</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo J, Troccaz S, Talabot-Ayer D, Rodriguez E, Palmer G. The severity of imiquimod-induced mouse skin inflammation is independent of endogenous IL-38 expression. PLoS ONE. 2018;13(3):e0194667. doi: 10.1371/journal.pone.0194667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0194667</ArticleId><ArticleId IdType="pmc">PMC5858842</ArticleId><ArticleId IdType="pubmed">29554104</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Y, Yu K, Wang X, Wang X, Ji Q, Zeng Q. Elevated plasma IL-38 concentrations in patients with acute ST-segment elevation myocardial infarction and their dynamics after reperfusion treatment. Mediators Inflamm. 2015;2015:490120. doi: 10.1155/2015/490120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/490120</ArticleId><ArticleId IdType="pmc">PMC4706979</ArticleId><ArticleId IdType="pubmed">26819499</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y, Lan Y, Zhong Y, Yu K, Xu W, Zhu R, Sun H, Ding Y, Wang Y, Zeng Q. Interleukin-38 alleviates cardiac remodelling after myocardial infarction. J Cell Mol Med. 2020;24(1):371&#x2013;384. doi: 10.1111/jcmm.14741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.14741</ArticleId><ArticleId IdType="pmc">PMC6933378</ArticleId><ArticleId IdType="pubmed">31746138</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Yu M, Lin QW, Cao AL, Yu X, Dong JH, Wang JP, Zhang JH, Wang M, Guo HP, Cheng X, Liao YH. Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis. J Immunol. 2010;185(7):4004&#x2013;4010. doi: 10.4049/jimmunol.1001718.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1001718</ArticleId><ArticleId IdType="pubmed">20802148</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu M, Tam LS, Zhu J, Jiao D, Liu H, Cai Z, Dong J, Kai Lam CW, Wong CK. In vivo anti-inflammatory activities of novel cytokine IL-38 in Murphy Roths Large (MRL)/lpr mice. Immunobiology. 2017;222(3):483&#x2013;493. doi: 10.1016/j.imbio.2016.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2016.10.012</ArticleId><ArticleId IdType="pubmed">27769564</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu F, Sharma S, Edwards J, Feigenbaum L, Zhu J. Dynamic expression of transcription factors T-bet and GATA-3 by regulatory T cells maintains immunotolerance. Nat Immunol. 2015;16(2):197&#x2013;206. doi: 10.1038/ni.3053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3053</ArticleId><ArticleId IdType="pmc">PMC4297509</ArticleId><ArticleId IdType="pubmed">25501630</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai YS, Lin SH, Zhang M, Deng L, Chen Y, Xie K, Wang CJ, Xu F. IL-38 is a biomarker for acute respiratory distress syndrome in humans and down-regulates Th17 differentiation in vivo. Clin Immunol. 2020;210:108315. doi: 10.1016/j.clim.2019.108315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2019.108315</ArticleId><ArticleId IdType="pubmed">31756565</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber SA. Coxsackievirus B3-induced myocarditis: infection of females during the estrus phase of the ovarian cycle leads to activation of T regulatory cells. Virology. 2008;378(2):292&#x2013;298. doi: 10.1016/j.virol.2008.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2008.05.015</ArticleId><ArticleId IdType="pmc">PMC2596296</ArticleId><ArticleId IdType="pubmed">18586295</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeilzadeh A, Pouyan S, Erfanmanesh M. Is Interleukin-38 a key player cytokine in atherosclerosis immune gene therapy? Med Hypotheses. 2019;125:139&#x2013;143. doi: 10.1016/j.mehy.2019.02.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2019.02.048</ArticleId><ArticleId IdType="pubmed">30902143</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Yuan X, Gao Q, Li Y, Li M. Interleukin-38 overexpression prevents bleomycin-induced mouse pulmonary fibrosis. Naunyn Schmiedebergs Arch Pharmacol. 2021;394(2):391&#x2013;399. doi: 10.1007/s00210-020-01920-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00210-020-01920-3</ArticleId><ArticleId IdType="pubmed">32577797</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>